Axon Enterprise (AXON) Falls -20% in 30 Days Despite Strong Q2 Revenue Growth
Key Takeaways
- Axon Enterprise shares declined roughly 20% over the trailing 30 days, from about $612.83 to $490.18, despite a strong second-quarter revenue report and raised guidance.
- The pullback was driven primarily by margin concerns and valuation de-rating rather than a slowdown in underlying demand.
- Over the last quarter, the stock is still up approximately 11%, having rallied sharply from mid-June lows before the recent decline.
- Second-quarter 2026 revenue rose 35.3% year over year to $904.4 million, while adjusted earnings per share fell 13.8% to $1.88.
- Management raised its full-year 2026 revenue growth outlook to 32–34%, but flagged higher memory costs and the absence of a repeat tariff-refund benefit.
- Wall Street consensus remains a "Moderate Buy," with an average price target near $721, even as near-term estimates have trended lower.
Axon Enterprise (AXON) Company Overview and Market Position
Axon Enterprise, Inc., headquartered in Scottsdale, Arizona, develops technology and equipment for law enforcement, public safety, and other government agencies. Its portfolio spans TASER conducted energy weapons, body-worn and in-car cameras such as Axon Body 4, and a connected cloud software stack built around Axon Evidence, digital evidence management, records, dispatch, and real-time operations tools.
The company operates through two segments: Connected Devices and Software & Services. Beyond its core hardware, Axon has expanded into artificial intelligence through its AI Era Plan (including Draft One and Axon Assistant), real-time operations via Fusus, counter-drone systems through Dedrone, and Axon 911. Investors follow the stock closely because Axon pairs recurring subscription revenue with rapid AI and drone adoption, positioning it as a growth leader within the public safety technology market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Axon Enterprise (AXON) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, Axon shares moved from a closing price of $612.83 to $490.18, a decline of approximately 20%. The stock reached an intra-quarter peak around $645.72 in mid-August before the selloff accelerated, with notable down days in late August and early September.
The broader quarterly picture is more mixed. Measured from a mid-June closing level of roughly $443.21, the stock is still up about 11% over the last quarter. That reflects a powerful rally through late June and July—driven by first-quarter results and AI and counter-drone momentum—that the subsequent 30-day pullback has only partially reversed. In short, Axon's recent decline is steep but comes off an elevated base established earlier in the quarter.
What Drove AXON Stock Price in the Last 30 Days
The largest single catalyst was Axon's second-quarter 2026 earnings release. Revenue of $904.4 million rose 35.3% year over year and beat consensus, and management raised its full-year revenue growth outlook to 32–34%. However, adjusted earnings per share of $1.88 declined 13.8% year over year and narrowly missed estimates, and shares fell in after-hours trading as investors focused on margins.
Management indicated that third-quarter margins would absorb higher memory costs without the tariff-refund benefit that padded second-quarter results. Adjusted gross margin declined to 62.9% from 63.3% a year earlier, pressured by a higher mix of professional services revenue and the scaling of newer products. At a valuation of roughly 200 times trailing earnings, any margin softness triggered a sharp de-rating.
Additional factors weighed on sentiment. Insider sales under pre-arranged Rule 10b5-1 plans—including transactions by CEO Patrick W. Smith and President Joshua Isner—added to the cautious tone. Broader scrutiny of surveillance technology, including automated license plate reader controversies affecting other companies in the sector, also contributed to repricing risk across public safety technology names. Notably, Wall Street's long-term stance remained constructive: Barclays raised its price target to $688, Needham reiterated a Buy with a $750 target, and Goldman Sachs maintained a Buy rating at $715.
What Drove AXON Stock Performance Over the Last Quarter
The quarterly advance was anchored by Axon's first-quarter 2026 results, which delivered revenue of $807 million, up 34% year over year, with AI-related product revenue up more than 700% and counter-drone revenue up more than 300%. Management raised its full-year guidance and highlighted strong demand for TASER 10, Axon Body 4, and Dedrone systems.
Through the summer, investor enthusiasm centered on the scaling of the AI Era Plan, which grew nearly 700% year over year, and on Dedrone, which surpassed $100 million in quarterly revenue after supporting all 11 U.S. World Cup stadiums. Annual recurring revenue reached $1.6 billion with net revenue retention of 126%, and future contracted bookings climbed 41% to $15.1 billion. These growth metrics supported the rally that carried the stock to its August peak before margin and valuation concerns triggered the recent pullback.
AXON Stock Forecast Drivers: What Investors Should Watch Next
Investors will be watching Axon's third-quarter earnings for evidence on how memory costs and product mix are affecting margins, as well as whether the company sustains its 32–34% revenue growth trajectory. Management has guided third-quarter body camera shipments up 20–30% sequentially and expects the fourth quarter to be the strongest period of the year.
Key themes include continued AI Era Plan adoption, Dedrone demand beyond the World Cup cycle, and the rollout of the Safer Skies Act's $250 million in federal counter-drone grants. Regulatory sentiment around surveillance and license plate reader technology also remains a factor to monitor. Finally, Axon's premium valuation—well above peers such as Motorola Solutions, Teledyne Technologies, and Woodward—means that margin execution and estimate revisions will likely continue to drive near-term share price volatility. From what I see, I’m watching this closely as the company reports next.
My Experience with Tickeron’s AI Trading Bots
One tool I find helpful for monitoring momentum around names like this is Tickeron’s AI Trading Bots. It lets me review a range of automated strategies across different timeframes and see which ones align with current market conditions for volatile growth stocks. I use it as part of my routine research to cross-check sentiment and potential setups without replacing my own analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
AXON in -2.46% downward trend, sliding for three consecutive days on October 05, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where AXON declined for three days, in 198 of 285 cases, the price declined further within the following month. The odds of a continued downward trend are 69%.
Technical Analysis (Indicators)
Bearish Trend Analysis
AXON moved below its 50-day moving average on September 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for AXON crossed bearishly below the 50-day moving average on September 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
The Aroon Indicator for AXON entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AXON's RSI Indicator exited the oversold zone, 23 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for AXON just turned positive on October 06, 2026. Looking at past instances where AXON's MACD turned positive, the stock continued to rise in 32 of 39 cases over the following month. The odds of a continued upward trend are 82%.
Following a +2.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 279 of 374 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 37 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock better than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.390) is normal, around the industry mean (6.305). AXON has a moderately high P/E Ratio (176.979) as compared to the industry average of (58.116). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (2.564). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.330).
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry AerospaceDefense
Advertisement